Suppr超能文献

肝细胞癌微创治疗的最新研究进展

The latest research progress on minimally invasive treatments for hepatocellular carcinoma.

作者信息

Zou Ya-Wen, Ren Zhi-Gang, Sun Ying, Liu Zhen-Guo, Hu Xiao-Bo, Wang Hai-Yu, Yu Zu-Jiang

机构信息

Department of Infectious Diseases, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Key Laboratory of Pulsed Power Translational Medicine of Zhejiang Province, 2959 Yuhangtang Road, Hangzhou 310000, China; Gene Hospital of Henan Province; Precision Medicine Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

Department of Infectious Diseases, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Gene Hospital of Henan Province; Precision Medicine Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

出版信息

Hepatobiliary Pancreat Dis Int. 2023 Feb;22(1):54-63. doi: 10.1016/j.hbpd.2022.08.004. Epub 2022 Aug 19.

Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide. Due to the high prevalence of hepatitis B virus (HBV) infection in China, the incidence of HCC in China is high, and liver cirrhosis caused by chronic hepatitis also brings great challenges to treatment. This paper reviewed the latest research progress on minimally invasive treatments for HCC, including percutaneous thermal ablation and new nonthermal ablation techniques, and introduced the principles, advantages, and clinical applications of various therapeutic methods in detail.

DATA SOURCES

The data of treatments for HCC were systematically collected from the PubMed, ScienceDirect, American Chemical Society and Web of Science databases published in English, using "minimally invasive" and "hepatocellular carcinoma" or "liver cancer" as the keywords.

RESULTS

Percutaneous thermal ablation is still a first-line strategy for the minimally invasive treatment of HCC. The effect of microwave ablation (MWA) on downgrading treatment before liver transplantation is better than that of radiofrequency ablation (RFA), while RFA is more widely used in the clinical practice. High-intensity focused ultrasound (HIFU) is mainly used for the palliative treatment of advanced liver cancer. Electrochemotherapy (ECT) delivers chemotherapeutic drugs to the target cells while reducing the blood supply around HCC. Irreversible electroporation (IRE) uses a microsecond-pulsed electric field that induces apoptosis and necrosis and triggers a systemic immune response. The nanosecond pulsed electric field (nsPEF) has achieved a good response in the ablation of mice with HCC, but it has not been reported in China for the treatment of human HCC.

CONCLUSIONS

A variety of minimally invasive treatments provide a sufficient survival advantage for HCC patients. Nonthermal ablation will lead to a new wave with its unique advantage of antitumor recurrence and metastasis.

摘要

背景

肝细胞癌(HCC)是全球癌症相关死亡的第四大主要原因。由于中国乙肝病毒(HBV)感染率高,中国HCC的发病率很高,慢性肝炎引起的肝硬化也给治疗带来了巨大挑战。本文综述了HCC微创治疗的最新研究进展,包括经皮热消融和新的非热消融技术,并详细介绍了各种治疗方法的原理、优势及临床应用。

数据来源

以“微创”和“肝细胞癌”或“肝癌”为关键词,从PubMed、ScienceDirect、美国化学学会和Web of Science数据库中系统收集英文发表的HCC治疗数据。

结果

经皮热消融仍是HCC微创治疗的一线策略。微波消融(MWA)在肝移植前降期治疗中的效果优于射频消融(RFA),而RFA在临床实践中应用更为广泛。高强度聚焦超声(HIFU)主要用于晚期肝癌的姑息治疗。电化学疗法(ECT)在将化疗药物输送到靶细胞的同时减少HCC周围的血液供应。不可逆电穿孔(IRE)使用微秒级脉冲电场诱导细胞凋亡和坏死,并引发全身免疫反应。纳秒级脉冲电场(nsPEF)在HCC小鼠消融中取得了良好反应,但在中国尚未见用于治疗人类HCC的报道。

结论

多种微创治疗为HCC患者提供了足够的生存优势。非热消融将以其独特的抗肿瘤复发和转移优势引领新的浪潮。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验